CSPC Pharmaceutical Group's (HKG:1093) developed Amphotericin B Liposome for injection was approved for drug registration by the National Medical Products Administration of China, a Monday filing with the Hong Kong Exchange said.
Amphotericin B is a type of polyene antibiotics and is used for the prevention and treatment of invasive fungal diseases.
The drug as compared to its competitors in the market, mainly exists in the liposomal form in the bloodstream, substantially reducing the binding of free amphotericin B to renal tubular epithelial cells, which results in a decrease in infusion reactions, significant reduction in drug nephrotoxicity, shortened administration duration, increase in dosage and improvement of therapeutic index.
The company's shares were up nearly 2% in recent trade.
Price (HKD): $4.64, Change: $+0.070, Percent Change: +1.53%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。